<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02370888</url>
  </required_header>
  <id_info>
    <org_study_id>WIRB20151509</org_study_id>
    <secondary_id>RV-CL-AML-PI-002987</secondary_id>
    <nct_id>NCT02370888</nct_id>
  </id_info>
  <brief_title>Lenalidomide After Allo-Hematopoietic Cell Transplant (HCT) in Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndromes (MDS) Subjects With Minimal Residual Disease</brief_title>
  <acronym>UF-BMT-MRD-101</acronym>
  <official_title>A Phase I Clinical Trial to Evaluate the Maximally Tolerated Dose (MTD), Dose Limiting Toxicities (DLTs) and Safety Profiles of Increasing Doses of Lenalidomide After Allo-HCT in AML and MDS Subjects With Minimal Residual Disease (MRD) Detected by the CD34+ Mixed Chimerism Analysis (UF-BMT-MRD-101)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the maximum tolerated dose, dose limiting side
      effects, and the safety of increasing doses of lenalidomide in patients with AML and MDS who
      have a small amount of detectable disease after allogeneic stem cell transplant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All subjects entering the screening phase will receive a unique subject number. This number
      will be used to identify the subject throughout the study. Additional test to include:
      physical examinations, blood tests, and if applicable pregnancy test will be performed as
      part of participation in this research study.

      Lenalidomide will be administered for a total of 42 days. The starting dose will be 2.5 mg
      given orally every other day on days 1-21 of a 28-day cycle for 2 cycles. Dose escalations
      and de-escalations will be made until the maximum tolerated dose is reached.

      The dose levels of lenalidomide will be as follows:

      Dose Level 1: 2.5 mg

      Dose Level 2: 2.5 mg

      Dose Level 3: 5 mg

      Dose Level 4: 7.5 mg

      Doses should be taken at approximately the same time each day.

      Subjects must be instructed to swallow lenalidomide capsules whole with water at the same
      time each day. Do not break, chew or open the capsules.

      Each subject will keep an accurate record of lenalidomide dosing on the Subject Dosing Diary.
      This diary will be kept in the research record as source documentation of lenalidomide
      dosing. Study personnel will review the dosing instructions with each subject at each study
      visit. Subjects will be asked to bring any unused drug and empty drug containers to the study
      site at the next visit for reconciliation with the Subject Dosing Diary.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow accrual
  </why_stopped>
  <start_date type="Actual">May 16, 2016</start_date>
  <completion_date type="Actual">May 31, 2019</completion_date>
  <primary_completion_date type="Actual">May 31, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of Lenalidomide</measure>
    <time_frame>Up to 72 days</time_frame>
    <description>To determine safety and the maximum tolerated dose of lenalidomide after allo-HCT in AML and MDS subjects with MRD detected by the CD34+ mixed chimerism analysis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CD34+ Mixed Chimerism</measure>
    <time_frame>Up to 120 days</time_frame>
    <description>To monitor changes in the CD34+ mixed chimerism after allo-HCT in AML and MDS subjects with detectable MRD in response to escalating doses of lenalidomide.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Leukemia, Myeloid</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>Lenalidomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lenalidomide will be administered for a total of 42 days.
The dose levels of lenalidomide will be as follows:
Dose Level 1: 2.5 mg PO QOD Day 1-21 for 28-day cycle X 2 cycles
Dose Level 2: 2.5 mg PO QD Day 1-21 for 28-day cycle X 2 cycles
Dose Level 3: 5 mg PO QD Day 1-21 for 28-day cycle X 2 cycles
Dose Level 4: 7.5 mg PO QD Day 1-21 for 28-day cycle X 2 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide</intervention_name>
    <description>Subjects will be enrolled in cohorts of three (3). Lenalidomide will be administered for 21 consecutive days in a 28 day cycle X 2 cycles. The starting dose will be 2.5 mg given orally every other day for 21 days.</description>
    <arm_group_label>Lenalidomide</arm_group_label>
    <other_name>Revlimid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects must be at least 18 years of age;

          2. Subjects must be post-allogeneic transplant from any donor source;

          3. Subjects must have either:

               1. High risk CD34+ AML (de novo or secondary, and any WHO 2008 classification
                  excluding acute promyelocytic leukemia). High risk AML is defined as (a) disease
                  status beyond complete remission (CR) #1 at transplant or (b) treatment related
                  AML or (c) presence of adverse cytogenetics including inv(3); t(3;3); t(6;9);
                  t(v;11); -5 or del(5q); -7; abnl(17p) or complex karyotype; or

               2. High risk CD34+ MDS (WHO 2008 classification). High risk is defined as (a) blast
                  count ≥5% at the time of transplant or (b) treatment related MD or (c) presence
                  of adverse cytogenetics including -7/del7q or complex karyotype;

          4. For AML subjects, they must have a documented CR within 45 days prior to allo-HCT;

          5. For MDS subjects, they must have &lt; 20% myeloblasts in the bone marrow within 45 days
             prior to allo-HCT;

          6. Subject Karnofsky performance status must be ≥ 70;

          7. Subjects must be platelet transfusion independent (Platelet transfusion independence
             is defined as 7 days or greater without a platelet transfusion);

          8. Neutrophil count ≥ 1.0 thou/mm3 and platelet count ≥ 30 thou/mm3;

          9. Subjects must have total bilirubin ≤ 2 mg/dL;

         10. Subjects must have serum AST and ALT levels ≤ 2.5 times upper limit of normal;

         11. Subjects must have serum creatinine &lt; 2.5 times upper limit of normal and a calculated
             creatinine clearance &gt; 30 ml/min by Cockcroft-Gault formula (see Appendix I:
             Cockcroft-Gault Creatinine Clearance Calculation);

         12. All study participants who will receive lenalidomide based on the CD34+ chimerism
             testing must be registered into the mandatory Revlimid REMS® program, and be willing
             and able to comply with the requirements of the REMS® program;

         13. Females of child-bearing potential (i.e., women who are premenopausal or not
             surgically sterile) may participate, provided they meet the following conditions:

             a) Females of reproductive potential must adhere to the scheduled pregnancy testing as
             required in the Revlimid REMS® program; and

         14. Written, voluntary informed consent, willingness, and ability to comply with all study
             procedures.

        Exclusion Criteria:

          1. CD34- AML or MDS;

          2. Inability to give informed consent;

          3. Uncontrolled active infection(s) requiring intravenous antibiotics;

          4. Known or suspected hypersensitivity to lenalidomide;

          5. Grade II-IV acute GVHD or extensive GVHD;

          6. Not able to swallow the lenalidomide capsule as a whole;

          7. Female subjects who are pregnant or nursing.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maxim N. Norkin, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida Shands Cancer Center</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>February 10, 2015</study_first_submitted>
  <study_first_submitted_qc>February 24, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2015</study_first_posted>
  <results_first_submitted>September 25, 2019</results_first_submitted>
  <results_first_submitted_qc>December 17, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 13, 2020</results_first_posted>
  <last_update_submitted>January 13, 2020</last_update_submitted>
  <last_update_submitted_qc>January 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lenalidomide</keyword>
  <keyword>Hematopoietic Stem Cell Transplantation</keyword>
  <keyword>Peripheral Blood Stem Cell Transplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Neoplasm, Residual</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenalidomide</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 25, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/88/NCT02370888/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Per protocol, enrollment is completion of informed consent. 11 subjects were enrolled- 2 did not meet eligibility and 9 did. Of the 9 eligible subjects- 3 received protocol treatment assignment, 5 did not have their chimerism drop, per protocol, below 90% at day 60 or 90 post-transplant, and 1 withdrew consent prior to assignment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dose Escalation of Lenalidomide</title>
          <description>Participants in the Arm only received Dose Level 1: 2.5 mg PO QOD Day 1-21 for 28-day cycle X 2 cycles</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Proceed to Treatment</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>disease progression</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>did not meet chimerism criteria</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Subsequent cohort requirements for analysis not met.</population>
      <group_list>
        <group group_id="B1">
          <title>Dose Level 1</title>
          <description>2.5 mg PO QOD Day 1-21 for 28 day cycle X 2 Enrolled 3 subjects</description>
        </group>
        <group group_id="B2">
          <title>Dose Level 2</title>
          <description>2.5 mg PO QD Day 1-21 for 28 day cycle X 2 cycles</description>
        </group>
        <group group_id="B3">
          <title>Dose Level 3</title>
          <description>5 mg PO QD Day 1-21 for 28 day cycle X 2 cycles</description>
        </group>
        <group group_id="B4">
          <title>Dose Level 4</title>
          <description>7.5 mg PO QD Day 1-21 for 28 day cycle X 2 cycles</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="0"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="0"/>
            <count group_id="B5" value="3"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Gender</title>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Participants with CD34 donor chimerism drop</title>
          <description>The number of study participants who experienced a CD34+ donor chimerism drop of less than or equal to 90% in allo-hematopoietic stem cell transplantation patients. CD34+ chimerism measurement is obtained via a peripheral blood draw.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose (MTD) of Lenalidomide</title>
        <description>To determine safety and the maximum tolerated dose of lenalidomide after allo-HCT in AML and MDS subjects with MRD detected by the CD34+ mixed chimerism analysis.</description>
        <time_frame>Up to 72 days</time_frame>
        <population>Cohort requirements for analysis not met. MTD could not be assessed as only a single dose level was tested. No dose escalation was performed.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level 1</title>
            <description>Lenalidomide 2.5 mg by mouth every other day for twenty-one days of a 28 day cycle for 2 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose (MTD) of Lenalidomide</title>
          <description>To determine safety and the maximum tolerated dose of lenalidomide after allo-HCT in AML and MDS subjects with MRD detected by the CD34+ mixed chimerism analysis.</description>
          <population>Cohort requirements for analysis not met. MTD could not be assessed as only a single dose level was tested. No dose escalation was performed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>CD34+ Mixed Chimerism</title>
        <description>To monitor changes in the CD34+ mixed chimerism after allo-HCT in AML and MDS subjects with detectable MRD in response to escalating doses of lenalidomide.</description>
        <time_frame>Up to 120 days</time_frame>
        <population>No participant met the requirements for the efficacy population (at least 21 days of the study drug and at least one post-cycle efficacy assessment). Therefore, no data were collected for this assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Dose Level 1</title>
            <description>Lenalidomide 2.5 mg by mouth every other day for twenty-one days of a 28 day cycle for two cycles.</description>
          </group>
          <group group_id="O2">
            <title>Dose Level 2</title>
            <description>Lenalidomide 2.5 mg by mouth daily for twenty-one days of a 28 day cycle for two cycles.</description>
          </group>
          <group group_id="O3">
            <title>Dose Level 3</title>
            <description>Lenalidomide 5 mg by mouth daily for twenty-one days of a 28 day cycle for 2 cycles.</description>
          </group>
          <group group_id="O4">
            <title>Dose Level 4</title>
            <description>Lenalidomide 7.5 mg by mouth daily for twenty-one days of a 28 day cycle for 2 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>CD34+ Mixed Chimerism</title>
          <description>To monitor changes in the CD34+ mixed chimerism after allo-HCT in AML and MDS subjects with detectable MRD in response to escalating doses of lenalidomide.</description>
          <population>No participant met the requirements for the efficacy population (at least 21 days of the study drug and at least one post-cycle efficacy assessment). Therefore, no data were collected for this assessment.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>9 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Dose Level 1: 2.5 mg PO QOD Day 1-21 for 28 Day Cycle X 2</title>
          <description>Subjects will be enrolled in cohorts of three (3). Lenalidomide will be administered for 21 consecutive days in a 28 day cycle X 2 cycles.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>Other</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and lymphatic system disorders</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders and administration site conditions</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigations</sub_title>
                <counts group_id="E1" events="18" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and nutrition disorders</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders</sub_title>
                <counts group_id="E1" events="10" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Archana Narasanna, Project Manager</name_or_title>
      <organization>Univeristy of Florida Health Cancer Center</organization>
      <phone>(352) 273-6772</phone>
      <email>PMO@cancer.ufl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

